BioStem Technologies Inc.
BioStem Technologies Inc. is a biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care and regenerative therapies. BioStem Technologies Inc. provides tissue-based solutions used in surgical and wound care settings, with products designed to support soft tissue coverage and repair. Its portfolio includes structural tissue allografts and human connective tissue matrices such as Vendaje, Vendaje AC, Vendaje OPTIC, American Amnion, and American Amnion AC. The company also uses its proprietary BioRetain processing method to preserve the natural properties of perinatal tissue while producing its biologic products. BioStem Technologies Inc. serves clinicians and healthcare providers across specialties where tissue repair and regenerative medicine are used, making it a specialized player in the biologics and wound care market.
$2.09
+$0.05 (+2.45%)
EOD Oct 16, 2026
10.34% operating margin is respectable but not wide. ROIC at 124.82%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 1708.9% YoY with margins expanding 57.0pp.
Even for strong businesses, today's 1x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
1.4x earnings, 1.5x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$302M
▲ +1708.9% YoY
Net Income (FY)
$32M
▲ +475.9% YoY
Op. Margin
10.34%
▲ +57.0pp YoY
ROIC
124.82%
▲ +250.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$24M
▲ +748.4% YoY
Op. Cash Flow (FY)
$24M
▲ +799.5% YoY
Net Debt
-$18M
Net Cash Position
Cash & Equiv.
$23M
3Y CAGR: +311.2%
Continue Research
Is BioStem Technologies (BSEM) overvalued?
At a P/E of 1.4 and a price-to-free-cash-flow of 1.5, BioStem Technologies (BSEM) trades below a two-stage DCF intrinsic value of about $35.63 per share, so at $2.09 the stock looks undervalued (1,604.7% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioStem Technologies scores 84/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is BioStem Technologies's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $35.63 per share for BSEM, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $26.72. At today's $2.09, that puts the stock about 1,604.7% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is BioStem Technologies a high-quality business?+
BioStem Technologies scores 84 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 10.3% operating margin and a 124.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is BioStem Technologies a good stock to buy right now?+
That depends on valuation and quality together, not either alone. BSEM currently trades below its estimated intrinsic value and scores 84/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.